NCI-MATCH: Nivolumab shows promising activity in noncolorectal cancersNovember 15, 2017Immuno-oncologyGynecologic CancerGenitourinary CancerBreast Cancer
Gut bacteria influenced response to checkpoint inhibitorsNovember 14, 2017Immuno-oncologyMelanomaLung CancerGenitourinary Cancer
CheckMate 214: Updated results for RCC focus on PD-L1 expression, QOLNovember 13, 2017Renal Cell CarcinomaImmuno-oncology
Neoantigen profiling predicts response to immunotherapyNovember 8, 2017Immuno-oncologyLung CancerMelanomaGastroenterologyGastrointestinal Cancer
Nivolumab linked to CNS disorder in case reportNovember 2, 2017Immuno-oncologyPatient & Survivor Care
FDA approves second CAR-T therapyOctober 19, 2017Leukemia, Myelodysplasia, TransplantationImmuno-oncology
Keynote 040: Pembrolizumab misses efficacy endpoint in advanced HNSCCOctober 17, 2017Immuno-oncologyHead & Neck/Thyroid Cancers
Cascade of costs could push new gene therapy above $1 million per patientOctober 17, 2017Immuno-oncologyLeukemia, Myelodysplasia, Transplantation
Liquid biopsy predicts checkpoint inhibitor responseOctober 2, 2017Immuno-oncologyLung CancerMelanomaHead & Neck/Thyroid Cancers
Checkmate 214: Upfront nivo/ipi bests TKI in advanced RCCSeptember 28, 2017Renal Cell CarcinomaImmunotherapyImmuno-oncology
FDA approves pembrolizumab for gastric and GEJ adenocarcinomaSeptember 27, 2017GastroenterologyImmuno-oncologyGastrointestinal Cancer
Retrospective review: No difference in PFS, OS with radiation before PD-1/PD-L1 inhibitionSeptember 26, 2017Lung CancerImmuno-oncology
FDA approves nivolumab for HCC patientsSeptember 25, 2017GastroenterologyImmuno-oncologyGastrointestinal Cancer
CRP may predict survival after immunotherapy for lung cancerSeptember 20, 2017Immuno-oncologyLung CancerImmunotherapy
